rss

This article has a correction

Please see: BMJ Case Reports 2012;2012

BMJ Case Reports 2011; doi:10.1136/bcr.02.2011.3893
  • Novel treatment (new drug/intervention; established drug/procedure in new situation)

Plasmapheresis as rescue therapy for systemic lupus erthyematosus-associated diffuse alveolar haemorrhage

  1. Michael Robson2
  1. 1Department of Renal, Guy’s and St Thomas’ Hospital Trust, London, UK
  2. 2Department of Nephrology and Transplantation, Guy’s and St Thomas’ Hospital Trust, London, UK
  1. Correspondence to Dr Simon Claridge, simonclaridge{at}doctors.org.uk

Summary

Diffuse alveolar haemorrhage (DAH) is a rare complication of systemic lupus erythematosus (SLE), which can have a potentially lethal outcome. Conventional treatments of the condition include cyclophosphamide and intravenous immunoglobulins. Successful treatment with rituximab and plasmapheresis has also been described. The authors report the case of a woman recently diagnosed with SLE who developed DAH refractory to conventional treatment while on immunosuppressive treatment for class III lupus nephritis whose DAH responded to plasmapheresis.

Footnotes

  • Competing interests None.

  • Patient consent Obtained.

Register for free content

The full text of all Editor's Choice articles and summaries of every article are free without registration

The full text of Images in ... articles are free to registered users

Only fellows can access the full text of case reports (apart from Editor's Choice) - become a fellow today, or encourage your institution to, so that together we can grow and develop this resource

Don't forget to sign up for content alerts so you keep up to date with all the case reports as they are published, and let us know what you think by commenting on the Editor's blog

Navigate This Article